NcXHF

ABOU-ALFA ET AL
mors including HCC, has shown promise. 60 An expansion
study of MEDI4736 was initiated in multiple cancer types
including HCC. The study continues to enroll patients and
generate more mature follow-up data.
CUSTOMIZED THERAPY
Recent work by many groups has attempted to recognize
the key drivers and potential targets for advanced
HCC. 61,62 No clear patterns have evolved so far, short of
recognizing certain genetic variation in select cohort of
patients. A more global approach that attempts to evaluate
cohorts of patients with HCC with specifıc ethnicity and
etiology and that correlates genetic fındings with clinical
outcomes may make headway toward custom-made therapy
for patients with advanced HCC. One of such current
global efforts led by Memorial Sloan Kettering Cancer
Center is also attempting to interrogate the genetic profıle
of each patient into specifıc clusters that are yet to be discovered.
Disclosures of Potential Conflicts of Interest
Relationships are considered self-held and compensated unless otherwise noted. Relationships marked “L” indicate leadership positions. Relationships marked “I” are those held by an immediate
family member; those marked “B” are held by the author and an immediate family member. Institutional relationships are marked “Inst.” Relationships marked “U” are uncompensated.
Employment: None. Leadership Position: None. Stock or Other Ownership Interests: None. Honoraria: None. Consulting or Advisory Role: Ghassan
K. Abou-Alfa, Aduro Biotech (I), Astellas Pharma, AstraZeneca (I), Celgene, Celsion, Cipla, Exelixis, IntegraGen, Jennerex, Lilly/ImClone, MedImmune, Novartis,
Pharmacyclics (I), Sanofi (I), Silenseed (I), Vicus Therapeutics. Jorge A. Marrero, Bayer/Onyx, Onyx. Speakers’ Bureau: None. Research Funding: Ghassan
K. Abou-Alfa, Abbott Laboratories (Inst), Amgen (Inst), Bayer (Inst), Exelixis (Inst), Genentech (Inst), Lilly/ImClone (Inst), Novartis (Inst), Polaris (Inst), Roche
(Inst), Vicus Therapeutics (Inst). Patents, Royalties, or Other Intellectual Property: None. Expert Testimony: None. Travel, Accommodations,
Expenses: Ghassan K. Abou-Alfa, Polaris. Other Relationships: None.
References
1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;
379:1245-1255.
2. Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular
carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol
Biomarkers Prev. 2012;21:793-799.
3. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic
indicators of survival in cirrhosis: a systematic review of 118 studies.
J Hepatol. 2006;44:217-231.
4. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease
(MELD) and allocation of donor livers. Gastroenterology. 2003;124:
91-96.
5. Huitzil Melendez FD, Capanu M, O’Reilly EM, et al. Advanced hepatocellular
carcinoma: which staging systems best predict prognosis? J Clin
Oncol. 2010;28:2889-2895.
6. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifıes
an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:
96-100.
7. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated
HCV genotype 1 infection. N Engl J Med. 2014;370:1889-
1898.
8. Bourliere M, Sulkowski MS, Omata M, et al. An integrated safety and
effıcacy analysis of 500 patients with compensated cirrhosis treated
with ledipasvir/sofosbuvir with or without ribavirin. 65th Annual Meeting
of the American Association for the Study of Liver Diseases. November
7-11, 2014. Boston, Massachusetts. Abstract 82.
9. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-
450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:
1594-1603.
10. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir
with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;
370:1973-1982.
11. Kulik L, Chokechanachaisakul A. Evaluation and management of hepatocellular
carcinoma. Clin Liver Dis. 2015;19:23-43.
12. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the
treatment of small hepatocellular carcinomas in patients with cirrhosis.
N Engl J Med. 1996;334:693-699.
13. Pomfret E, Washburn K, Wald C, et al. Report of a national conference
on liver allocation in patients with hepatocellular carcinoma. Liver
Transpl. 2010;16:262-278.
14. Yao F, Kerlan R, Hirose R, et al. Excellent outcome following downstaging
of hepatocellular carcinoma prior to liver transplantation: an
intent-to-treat analysis. Hepatology. 2008;48:819-827.
15. Clavien P, Lesurtel M, Bossuyt P, et al. Recommendations for liver
transplantation for hepatocellular carcinoma: an international consensus
report. Lancet Oncol. 2012;13:11-22.
16. Prasad K, Young R, Burra P, et al. Summary of candidate selection and
expanded criteria for liver transplantation for hepatocellular carcinoma:
a review and consensus statement. Liver Transpl. 2011;Suppl 2:S81-S89.
17. Yao F, Ferrell L, Bass N, et al. Liver transplantation for hepatocellular
carcinoma: expansion of the tumor size limits does not adversely impact
survival. Hepatology. 2001;33:1394-1403.
18. Kashkoush S, El Moghazy W, Kawahara T, et al. Three-dimensional tumor
volume and serum alpha-fetoprotein are predictors of hepatocellular
carcinoma recurrence after liver transplantation: refıned selection
criteria. Clin Transplant. 2014;28:728-736.
19. Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer
before liver transplant: long-term outcome compared to tumors
within Milan criteria. Hepatology. Epub 2015 Feb 18.
20. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the
Milan criteria. Am J Transplant. 2008;8:1982-1989.
21. Takada Y, Tohyama T, Watanbe J. Biological markers of hepatocellular
carcinoma for use as selection criteria for liver transplantation. J Hepatobiliary
Pancreat Sci. 2014;19:195-205.
e218
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook